Qutenza

RSS

capsaicin

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Qutenza. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Qutenza.

This EPAR was last updated on 08/05/2019

Authorisation details

Product details
Name
Qutenza
Agency product number
EMEA/H/C/000909
Active substance
capsaicin
International non-proprietary name (INN) or common name
capsaicin
Therapeutic area (MeSH)
Neuralgia
Anatomical therapeutic chemical (ATC) code
N01BX04
Publication details
Marketing-authorisation holder
Grunenthal GmbH
Revision
12
Date of issue of marketing authorisation valid throughout the European Union
15/05/2009
Contact address
Zieglerstrasse 6
52078 Aachen
Germany

Product information

28/03/2019 Qutenza - EMEA/H/C/000909 - R/0047

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ANESTHETICS

Therapeutic indication

Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.

Assessment history

How useful was this page?

Add your rating